Skip to content

A prospective randomized, double-blind, controlled clinical study of virtual reality combined with pulsed radiofrequency in the treatment of zoster-associated neuralgia

A prospective randomized, double-blind, controlled clinical study of virtual reality combined with pulsed radiofrequency in the treatment of zoster-associated neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104772
Enrollment
Unknown
Registered
2025-06-23
Start date
2023-11-28
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

zoster-related pain

Interventions

VR group:The equipment adopts ReacoolMPT pain relief rehabilitation training software, turns on VR all-in-one machine, connects tablet and processor unit, assists patients to wear 3D goggles and helme
Control group:ReacoolMPT pain relief and rehabilitation training software in VR equipment was also used, but only 15-minute landscape videos were played for the patients.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 83 Years

Inclusion criteria

Inclusion criteria: 1. The subjects volunteered and signed the informed consent form for the trial. 2. The age is under 18 years old, female patients during pregnancy or lactation. 3. Patients with acute herpetic neuralgia, subacute herpetic neuralgia , post-herpetic neuralgia. 4. Patients with VAS >= 4 before treatment or severe adverse reactions (dizziness, drowsiness, etc.) after drug treatment. 5. Planning to receiving pulsed radiofrequency PRF therapy. 6. The cognitive function is normal, can describe the symptoms objectively and cooperate activel

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the inclusion criteria, or who are determined by the doctor to be unsuitable to participate in this trial. 2. Serious cardiopulmonary diseases. 3. Patients with severe hepatic and renal insufficiency. 4. Complicated with coagulation system disease or local infection. 5. VR devices can not be used. 6. Severe cardiac, hepatic and renal insufficiency. 7. Cognitive impairment, unable to communicate and unable to cooperate with the respondents. 8. The researchers believe that there are any reasons why they can not be selected.

Design outcomes

Primary

MeasureTime frame
pain relief rate after three months;

Secondary

MeasureTime frame
Pain relief rate at discharge;Pain relief rate after discharge 1 month;pain catastrophizing score;Morphine Milligram Equivalents;Type of medication;Pittsburgh Sleep Quality Index;Hospital Anxiety and Depression Scale;Satisfaction score;incidence of adverse reactions;

Countries

China

Contacts

Public ContactSong Li

West China Hospital,Sichuan University

song_li76@163.com+86 189 8060 1501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026